Review



antigen presenting cell lines apcs t2  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    ATCC antigen presenting cell lines apcs t2
    In Vitro Validation of a Genetically Engineered T-Cell Activation Model. (A) Schematic representation of the genetically modified Jurkat T-cell line designed to report T-cell activation via NFAT-driven eGFP expression. These cells are equipped with a TCR specific for HLA-A*02-restricted MART1, CD8 co-receptor, PD-1 receptor, and a dCas9-KRAB-MeCP2 transcriptional repression system. When co-cultured with <t>APCs/melanoma</t> cells expressing MART1, eGFP expression indicates robust T-cell activation. In certain melanoma cell lines, robust expression of surface PD-L1 can be achieved by pre-treatment for 24 hours with IFN-γ. (B) Validation of the NFAT-driven eGFP reporter functionality in the T-cell model using flow cytometry. Negligible T-cell activation is observed in the absence of antigen-presenting or tumor cells (quiescent state), while treatment with PMA and ionomycin results in near-total activation. (C) Comparative analysis of T-cell activation following co-culture with different antigen-presenting cells (APCs) pulsed with MART1 peptides and melanoma cell lines. 2D3s were co-cultured at a 1:2 tumor cell/APC to 2D3 TCR/dCas9 ratio for 20-24 hours. The 2D3 TCR/dCas9 T-cell line exhibits moderate activation with peptide-pulsed U266-B1 cells and pronounced activation with peptide-pulsed <t>T2</t> cells. Negative controls with non-peptide-pulsed APCs confirm assay specificity. As for melanoma cell lines, additional examination of checkpoint blockade with nivolumab and IFN-γ treatment effects on co-culture-mediated T-cell activation demonstrates distinct immune evasion mechanisms. All data shown represent the mean values of triplicate measurements, with error bars indicating the standard deviation.
    Antigen Presenting Cell Lines Apcs T2, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1631 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antigen+presenting+cell+lines+apcs+t2/pmc11532180-27-31-40?v=ATCC
    Average 97 stars, based on 1631 article reviews
    antigen presenting cell lines apcs t2 - by Bioz Stars, 2026-07
    97/100 stars

    Images

    1) Product Images from "A co-culture model to study modulators of tumor immune evasion through scalable arrayed CRISPR-interference screens"

    Article Title: A co-culture model to study modulators of tumor immune evasion through scalable arrayed CRISPR-interference screens

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2024.1444886

    In Vitro Validation of a Genetically Engineered T-Cell Activation Model. (A) Schematic representation of the genetically modified Jurkat T-cell line designed to report T-cell activation via NFAT-driven eGFP expression. These cells are equipped with a TCR specific for HLA-A*02-restricted MART1, CD8 co-receptor, PD-1 receptor, and a dCas9-KRAB-MeCP2 transcriptional repression system. When co-cultured with APCs/melanoma cells expressing MART1, eGFP expression indicates robust T-cell activation. In certain melanoma cell lines, robust expression of surface PD-L1 can be achieved by pre-treatment for 24 hours with IFN-γ. (B) Validation of the NFAT-driven eGFP reporter functionality in the T-cell model using flow cytometry. Negligible T-cell activation is observed in the absence of antigen-presenting or tumor cells (quiescent state), while treatment with PMA and ionomycin results in near-total activation. (C) Comparative analysis of T-cell activation following co-culture with different antigen-presenting cells (APCs) pulsed with MART1 peptides and melanoma cell lines. 2D3s were co-cultured at a 1:2 tumor cell/APC to 2D3 TCR/dCas9 ratio for 20-24 hours. The 2D3 TCR/dCas9 T-cell line exhibits moderate activation with peptide-pulsed U266-B1 cells and pronounced activation with peptide-pulsed T2 cells. Negative controls with non-peptide-pulsed APCs confirm assay specificity. As for melanoma cell lines, additional examination of checkpoint blockade with nivolumab and IFN-γ treatment effects on co-culture-mediated T-cell activation demonstrates distinct immune evasion mechanisms. All data shown represent the mean values of triplicate measurements, with error bars indicating the standard deviation.
    Figure Legend Snippet: In Vitro Validation of a Genetically Engineered T-Cell Activation Model. (A) Schematic representation of the genetically modified Jurkat T-cell line designed to report T-cell activation via NFAT-driven eGFP expression. These cells are equipped with a TCR specific for HLA-A*02-restricted MART1, CD8 co-receptor, PD-1 receptor, and a dCas9-KRAB-MeCP2 transcriptional repression system. When co-cultured with APCs/melanoma cells expressing MART1, eGFP expression indicates robust T-cell activation. In certain melanoma cell lines, robust expression of surface PD-L1 can be achieved by pre-treatment for 24 hours with IFN-γ. (B) Validation of the NFAT-driven eGFP reporter functionality in the T-cell model using flow cytometry. Negligible T-cell activation is observed in the absence of antigen-presenting or tumor cells (quiescent state), while treatment with PMA and ionomycin results in near-total activation. (C) Comparative analysis of T-cell activation following co-culture with different antigen-presenting cells (APCs) pulsed with MART1 peptides and melanoma cell lines. 2D3s were co-cultured at a 1:2 tumor cell/APC to 2D3 TCR/dCas9 ratio for 20-24 hours. The 2D3 TCR/dCas9 T-cell line exhibits moderate activation with peptide-pulsed U266-B1 cells and pronounced activation with peptide-pulsed T2 cells. Negative controls with non-peptide-pulsed APCs confirm assay specificity. As for melanoma cell lines, additional examination of checkpoint blockade with nivolumab and IFN-γ treatment effects on co-culture-mediated T-cell activation demonstrates distinct immune evasion mechanisms. All data shown represent the mean values of triplicate measurements, with error bars indicating the standard deviation.

    Techniques Used: In Vitro, Activation Assay, Genetically Modified, Expressing, Cell Culture, Flow Cytometry, Co-Culture Assay, Standard Deviation



    Similar Products

    antigen presenting cell lines apcs t2  (ATCC)
    97
    ATCC antigen presenting cell lines apcs t2
    In Vitro Validation of a Genetically Engineered T-Cell Activation Model. (A) Schematic representation of the genetically modified Jurkat T-cell line designed to report T-cell activation via NFAT-driven eGFP expression. These cells are equipped with a TCR specific for HLA-A*02-restricted MART1, CD8 co-receptor, PD-1 receptor, and a dCas9-KRAB-MeCP2 transcriptional repression system. When co-cultured with <t>APCs/melanoma</t> cells expressing MART1, eGFP expression indicates robust T-cell activation. In certain melanoma cell lines, robust expression of surface PD-L1 can be achieved by pre-treatment for 24 hours with IFN-γ. (B) Validation of the NFAT-driven eGFP reporter functionality in the T-cell model using flow cytometry. Negligible T-cell activation is observed in the absence of antigen-presenting or tumor cells (quiescent state), while treatment with PMA and ionomycin results in near-total activation. (C) Comparative analysis of T-cell activation following co-culture with different antigen-presenting cells (APCs) pulsed with MART1 peptides and melanoma cell lines. 2D3s were co-cultured at a 1:2 tumor cell/APC to 2D3 TCR/dCas9 ratio for 20-24 hours. The 2D3 TCR/dCas9 T-cell line exhibits moderate activation with peptide-pulsed U266-B1 cells and pronounced activation with peptide-pulsed <t>T2</t> cells. Negative controls with non-peptide-pulsed APCs confirm assay specificity. As for melanoma cell lines, additional examination of checkpoint blockade with nivolumab and IFN-γ treatment effects on co-culture-mediated T-cell activation demonstrates distinct immune evasion mechanisms. All data shown represent the mean values of triplicate measurements, with error bars indicating the standard deviation.
    Antigen Presenting Cell Lines Apcs T2, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antigen+presenting+cell+lines+apcs+t2/pmc11532180-27-31-40?v=ATCC
    Average 97 stars, based on 1 article reviews
    antigen presenting cell lines apcs t2 - by Bioz Stars, 2026-07
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    In Vitro Validation of a Genetically Engineered T-Cell Activation Model. (A) Schematic representation of the genetically modified Jurkat T-cell line designed to report T-cell activation via NFAT-driven eGFP expression. These cells are equipped with a TCR specific for HLA-A*02-restricted MART1, CD8 co-receptor, PD-1 receptor, and a dCas9-KRAB-MeCP2 transcriptional repression system. When co-cultured with APCs/melanoma cells expressing MART1, eGFP expression indicates robust T-cell activation. In certain melanoma cell lines, robust expression of surface PD-L1 can be achieved by pre-treatment for 24 hours with IFN-γ. (B) Validation of the NFAT-driven eGFP reporter functionality in the T-cell model using flow cytometry. Negligible T-cell activation is observed in the absence of antigen-presenting or tumor cells (quiescent state), while treatment with PMA and ionomycin results in near-total activation. (C) Comparative analysis of T-cell activation following co-culture with different antigen-presenting cells (APCs) pulsed with MART1 peptides and melanoma cell lines. 2D3s were co-cultured at a 1:2 tumor cell/APC to 2D3 TCR/dCas9 ratio for 20-24 hours. The 2D3 TCR/dCas9 T-cell line exhibits moderate activation with peptide-pulsed U266-B1 cells and pronounced activation with peptide-pulsed T2 cells. Negative controls with non-peptide-pulsed APCs confirm assay specificity. As for melanoma cell lines, additional examination of checkpoint blockade with nivolumab and IFN-γ treatment effects on co-culture-mediated T-cell activation demonstrates distinct immune evasion mechanisms. All data shown represent the mean values of triplicate measurements, with error bars indicating the standard deviation.

    Journal: Frontiers in Immunology

    Article Title: A co-culture model to study modulators of tumor immune evasion through scalable arrayed CRISPR-interference screens

    doi: 10.3389/fimmu.2024.1444886

    Figure Lengend Snippet: In Vitro Validation of a Genetically Engineered T-Cell Activation Model. (A) Schematic representation of the genetically modified Jurkat T-cell line designed to report T-cell activation via NFAT-driven eGFP expression. These cells are equipped with a TCR specific for HLA-A*02-restricted MART1, CD8 co-receptor, PD-1 receptor, and a dCas9-KRAB-MeCP2 transcriptional repression system. When co-cultured with APCs/melanoma cells expressing MART1, eGFP expression indicates robust T-cell activation. In certain melanoma cell lines, robust expression of surface PD-L1 can be achieved by pre-treatment for 24 hours with IFN-γ. (B) Validation of the NFAT-driven eGFP reporter functionality in the T-cell model using flow cytometry. Negligible T-cell activation is observed in the absence of antigen-presenting or tumor cells (quiescent state), while treatment with PMA and ionomycin results in near-total activation. (C) Comparative analysis of T-cell activation following co-culture with different antigen-presenting cells (APCs) pulsed with MART1 peptides and melanoma cell lines. 2D3s were co-cultured at a 1:2 tumor cell/APC to 2D3 TCR/dCas9 ratio for 20-24 hours. The 2D3 TCR/dCas9 T-cell line exhibits moderate activation with peptide-pulsed U266-B1 cells and pronounced activation with peptide-pulsed T2 cells. Negative controls with non-peptide-pulsed APCs confirm assay specificity. As for melanoma cell lines, additional examination of checkpoint blockade with nivolumab and IFN-γ treatment effects on co-culture-mediated T-cell activation demonstrates distinct immune evasion mechanisms. All data shown represent the mean values of triplicate measurements, with error bars indicating the standard deviation.

    Article Snippet: The embryonic kidney cell line HEK293T/17 (ATCC, Cat. #CRL-11268), the malignant melanoma cell lines MALME-3M (ATCC, Cat. #HTB64) and SK-MEL-5 (ATCC, Cat. #HTB-70), the 2D3 cell line, a Jurkat derivative, and antigen presenting cell lines (APCs) T2 (174 x CEM.T2, ATCC, Cat. #CRL-1992), and U266B1 (ATCC, Cat. #TIB-196) were employed in the study.

    Techniques: In Vitro, Activation Assay, Genetically Modified, Expressing, Cell Culture, Flow Cytometry, Co-Culture Assay, Standard Deviation